Medication Can't Do It All, Says Obesity and Weight Management Expert
Dr Caroline Apovian reminds primary care clinicians who care for patients with obesity that diet and lifestyle counseling are essential for maximum results.
DEA Extends Telehealth Prescribing Rule for Controlled Substances
The telehealth practice adopted in March 2020 at the start of the COVID public health emergency will be extended until November 11, 2023.
Primary Care and Physiatry: Complementary Tools for Full Recovery from Injury
The partnership between primary care and PM&R is a tool in each specialty's tool box, with the patient's return to full function the shared goal.
Boys with Overweight/Obesity Have Lower Testicular Volume, According to New Study
Participants with overweight or obesity had lower testicular volume than their healthy peers, putting them at risk for infertility later in adulthood.
Daily Dose: Sex‐Specific Reproductive Factors Augment CVD Risk in Women
Your daily dose of clinical news you may have missed.
Oral Contraceptive Gets Unanimous Recommendation for OTC Use from FDA Advisory Panel
Opill, a progestin-only oral contraceptive, if approved by the FDA, would be the first an only form of birth control in the US available without a physician's prescription.
Investigational Antiobesity Drug from Boehringer Ingelheim Meets Primary Endpoint in Phase 2 Trial
The dual GIP/GLP-1 receptor agonist was associated with a nearly 15% reduction in body weight in adults with overweight/obesity and without type 2 diabetes.
Improved Diabetes and Kidney Function Control With KidneyIntelX
Drs Aide Vega and Fernando Carnavali highlight the increased control in both diabetes and kidney function with the use of KidneyIntelX in patients with DKD.
Referral of High- and Low-Risk Groups in DKD
Aida Vega, MD, and Fernando Carnavali, MD, discuss the KidneyIntelX study and the rates of referrals of high-risk DKD patients to specialist care.
KidneyIntelX in DKD Study Population Characteristics
Aida Vega, MD, and Fernando Carnavali, MD, review the population characteristics of a study involving the use of KidneyIntelX in DKD.
Denosumab Superior to Alendronate for Reduction of Postmenopausal Fracture Risk in Real-world Study
Denosumab reduced RR of fracture vs alendronate across fracture types, eg, by 36% for hip fracture, by 43% for nonvertebral fractures, and by 30% for vertebral fractures.
Concussion Patients are Getting Younger: Bad News, Good News
A diagnosis of concussion in an 8-year-old who plays weekend soccer is, on its face, bad news; the good news is that 15 years ago, it might have gone unnoticed, untreated.
USPSTF: Begin Breast Cancer Screening at Age 40 (Not 50) Years for All Women
The lower recommended starting age for screening reflects rising cancer diagnoses among younger women and persistently high mortality rates among Black women.
Reproductive Factors in Women Contribute to Risk of Cardiovascular Disease, According to New Study
Results of a Mendelian randomization study showed earlier first birth, higher number of live births, and earlier menarche are all associated with increased CVD.
Daily Dose: AACE Updates Algorithm for Type 2 Diabetes Management
Women Underrepresented in Late-breaking Cardiovascular Clinical Trials, a New Analysis Finds
Sex-based disparities found in high-profile clinical trials presented at 3 key cardiology scientific meetings underscore the lack of progress made toward equitable inclusion in research.
Start Low, Go Slow with GLP-1 Receptor Agonists when Initiating Weight Management Therapy
GLP-1 RA side effects such as nausea and vomiting can be minimized by starting at the lowest available dose and titrating slowly; Dr Caroline Apovian explains why.
Antiobesity Medications Complement Lifestyle Change in Chronic Weight Management
GLP-1 receptor agonist-based medications for obesity modify gut hormone imbalances, making diet and lifestyle change far more effective, explains Caroline Apovian, MD.
Daily Dose: Medicinal Cannabis for Cancer-related Pain
AACE Releases Updated Algorithm for Managing Persons with Type 2 Diabetes
The 2023 algorithm emphasizes a complication-centric approach, beyond glucose levels, for determining first-line pharmacotherapy.